About Us | Contact

Dr. Jerome A. Barakos

Diagnostic Radiology California Pacific Medical Center- Van Ness Campus NPI1972558922
Update NPI

Open Payments

Note

The following payment details are based on a national transparency program known as the Sunshine Act that collects and publishes information about financial relationships between the health care industry (i.e. drug and device manufactures) and providers. These relationships may involve payment to providers for things such as research, speaking engagment, travel, gifts etc. Not all of these payment involve monetary compensations and may include batering of drugs or devices.

Total Payment Worth

$942,816.29
from 98 payments in the last 6 years

Total Cash or Cash Equivalent

$941,479.95
from 96 payments in the last 6 years

Total In-kind Items & Services

$1,336.34
from 2 payments in the last 6 years

Nature of Payments

Last 6 Years
Chart will render here...

Yearly Breakdown

Chart will render here...

Payment Details

Date Payment Type Form of Payment Item/Service Payment Amount
12/16/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $2642.50 Details
Payment from Biogen, Inc.
Payment Record ID 827771337
06/24/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $3586.25 Details
Payment from Biogen, Inc.
Payment Record ID 827771335
05/20/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $1132.50 Details
Payment from Biogen, Inc.
Payment Record ID 827771333
06/24/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $1510.00 Details
Payment from Biogen, Inc.
Payment Record ID 827771331
03/24/2021 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2265.00 Details
Payment from Biogen, Inc.
Payment Record ID 827771329
03/03/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $2265.00 Details
Payment from Biogen, Inc.
Payment Record ID 827771327
01/21/2021 General (Non-Research) Cash or cash equivalent Consulting Fee $2265.00 Details
Payment from Biogen, Inc.
Payment Record ID 827771325
01/15/2021 General (Non-Research) Cash or cash equivalent Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $2265.00 Details
Payment from Biogen, Inc.
Payment Record ID 827771323
01/13/2021 Research Cash or cash equivalent $99813.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Phase IIB Dose Range Monotherapy with Population PK
Payment Record ID 819890451
08/12/2021 Research Cash or cash equivalent $1980.00 Details
Payment from Eli Lilly and Company
Paymment Research Study DONANEMAB FOLLOW-ON STUDY: SAFETY, TOLERABILITY, AND EFFICACY IN SYMPTOMATIC ALZHEIMER'S DISEASE WITH VALIDATION OF REMOTE NEUROPSYCHOLOGICAL ASSESSMENTS
Clinical Trials Gov ID NCT04640077
Payment Record ID 819445855
01/13/2021 Research Cash or cash equivalent $5600.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE
Clinical Trials Gov ID NCT04451408
Payment Record ID 819445853
02/10/2021 Research Cash or cash equivalent $4860.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE
Payment Record ID 819445089
01/13/2021 Research Cash or cash equivalent $136610.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT04437511
Payment Record ID 819444783
08/20/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $1600.00 Details
Payment from Biogen, Inc.
Payment Record ID 807274493
09/30/2020 Research In-kind items and services Drug $1087.49 Details
Payment from F. Hoffmann-La Roche AG
Paymment Research Study A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Prodromal to Mild Alzheimer's Disease, A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Prodromal to Mild Alzheimer's Disease
Payment Record ID 742982915
06/30/2020 Research In-kind items and services Drug $248.85 Details
Payment from F. Hoffmann-La Roche AG
Paymment Research Study A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Prodromal to Mild Alzheimer's Disease, A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Study of Gantenerumab in Patients with Prodromal to Mild Alzheimer's Disease
Payment Record ID 742982903
05/21/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $1510.00 Details
Payment from Biogen, Inc.
Payment Record ID 737264183
11/10/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3020.00 Details
Payment from Biogen, Inc.
Payment Record ID 737264181
10/19/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3020.00 Details
Payment from Biogen, Inc.
Payment Record ID 737264179
09/15/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3020.00 Details
Payment from Biogen, Inc.
Payment Record ID 737264177
09/02/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3020.00 Details
Payment from Biogen, Inc.
Payment Record ID 737264175
07/22/2020 General (Non-Research) Cash or cash equivalent Consulting Fee $3020.00 Details
Payment from Biogen, Inc.
Payment Record ID 737264173
01/08/2020 Research Cash or cash equivalent $30236.00 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Phase IIB Dose Range Monotherapy with Population PK
Payment Record ID 736765371
09/09/2020 Research Cash or cash equivalent $1090.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF LY3372993 IN PARTICIPANTS WITH ALZHEIMER'S DISEASE
Clinical Trials Gov ID NCT04451408
Payment Record ID 728721909
09/09/2020 Research Cash or cash equivalent $3390.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT04437511
Payment Record ID 728720883
01/08/2020 Research Cash or cash equivalent $20150.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT03367403
Payment Record ID 728720149
01/08/2020 Research Cash or cash equivalent $9450.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE
Payment Record ID 728720047
01/23/2019 Research Cash or cash equivalent $500.00 Details
Payment from Eli Lilly and Company
Paymment Research Study MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3303560 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT03019536
Payment Record ID 654283407
01/23/2019 Research Cash or cash equivalent $300.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY
Clinical Trials Gov ID NCT02972658
Payment Record ID 654282971
01/23/2019 Research Cash or cash equivalent $38650.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT03367403
Payment Record ID 654282843
06/03/2019 Research Cash or cash equivalent $270.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A STUDY OF LY3372993 IN HEALTHY PARTICIPANTS AND PARTICIPANTS WITH ALZHEIMER'S DISEASE (AD)
Clinical Trials Gov ID NCT03720548
Payment Record ID 654282837
01/23/2019 Research Cash or cash equivalent $25620.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE
Payment Record ID 654282835
01/23/2019 Research Cash or cash equivalent $200.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02783573
Payment Record ID 654282833
01/23/2019 Research Cash or cash equivalent $150.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 654282613
05/08/2019 Research Cash or cash equivalent $9094.70 Details
Payment from E.R. Squibb & Sons, L.L.C.
Paymment Research Study Phase IIB Dose Range Monotherapy with Population PK
Payment Record ID 639764991
08/02/2018 Research Cash or cash equivalent $2250.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3303560 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE
Payment Record ID 585602901
07/03/2018 Research Cash or cash equivalent $2475.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, DELAYED-START STUDY OF LY3314814 AZD3293 IN EARLY ALZHEIMER'S DISEASE DEMENTIA EXTENSION OF STUDY AZES, THE AMARANTH STUDY
Clinical Trials Gov ID NCT02972658
Payment Record ID 585602899
02/22/2018 Research Cash or cash equivalent $6350.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT03367403
Payment Record ID 585602897
02/15/2018 Research Cash or cash equivalent $4400.00 Details
Payment from Eli Lilly and Company
Paymment Research Study MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3303560 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT03019536
Payment Record ID 585602895
02/15/2018 Research Cash or cash equivalent $76400.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02783573
Payment Record ID 585602893
02/15/2018 Research Cash or cash equivalent $44925.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 585602891
02/15/2018 Research Cash or cash equivalent $7700.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02791191
Payment Record ID 585602889
12/01/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $700.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504880419
12/20/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $100.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504880411
04/09/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $700.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504155271
05/24/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $550.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504155227
04/26/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $100.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504155223
06/15/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $100.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 504154171
01/05/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $7600.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503589193
01/05/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $5275.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503588853
02/24/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503588847
01/05/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $400.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503586591
01/19/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $6700.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503586141
01/19/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $4500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503585755
01/19/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $400.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503585747
02/24/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $2300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503585745
02/24/2017 General (Non-Research) Cash or cash equivalent Consulting Fee $600.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 503583559
01/05/2017 Research Cash or cash equivalent $42675.00 Details
Payment from Eli Lilly and Company
Paymment Research Study EFFECT OF PASSIVE IMMUNIZATION ON THE PROGRESSION OF MILD ALZHEIMERS DISEASE - SOLANEZUMAB -LY2062430- VERSUS PLACEBO
Clinical Trials Gov ID NCT01900665
Payment Record ID 457097327
01/05/2017 Research Cash or cash equivalent $1000.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, PHASE 3, MULTICENTER, PLACEBO-CONTROLLED STUDY OF EFFICACY AND SAFETY OF SOLANEZUMAB VERSUS PLACEBO IN PRODROMAL ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT02760602
Payment Record ID 457097325
01/05/2017 Research Cash or cash equivalent $18600.00 Details
Payment from Eli Lilly and Company
Paymment Research Study CONTINUED EFFICACY AND SAFETY MONITORING OF SOLANEZUMAB, AN ANTI-AMYLOID ANTIBODY IN PATIENTS WITH ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT01127633
Payment Record ID 457097323
12/20/2017 Research Cash or cash equivalent $75.00 Details
Payment from Eli Lilly and Company
Paymment Research Study ASSESSMENT OF SAFETY, TOLERABILITY AND EFFICACY OF LY3002813 ALONE AND IN COMBINATION WITH LY3202626 IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT03367403
Payment Record ID 457097321
06/15/2017 Research Cash or cash equivalent $2400.00 Details
Payment from Eli Lilly and Company
Paymment Research Study MULTIPLE-DOSE, DOSE-ESCALATION STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF LY3303560 IN PATIENTS WITH MILD COGNITIVE IMPAIRMENT DUE TO ALZHEIMERS DISEASE OR MILD TO MODERATE ALZHEIMERS DISEASE
Clinical Trials Gov ID NCT03019536
Payment Record ID 457097319
01/05/2017 Research Cash or cash equivalent $8000.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A STUDY OF LY3202626 ON DISEASE PROGRESSION IN PARTICIPANTS WITH MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02791191
Payment Record ID 457097317
01/05/2017 Research Cash or cash equivalent $50000.00 Details
Payment from Eli Lilly and Company
Paymment Research Study A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND DELAYED-START STUDY OF LY3314814 IN MILD ALZHEIMERS DISEASE DEMENTIA
Clinical Trials Gov ID NCT02783573
Payment Record ID 457097315
01/05/2017 Research Cash or cash equivalent $75862.50 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 457097313
11/22/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $400.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406484874
11/22/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $6525.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406483936
11/22/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $5300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406483934
10/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406483932
10/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $2125.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406483930
10/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $200.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406483928
08/25/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $8800.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406081030
09/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $900.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406077814
08/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $7950.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406077550
09/21/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $6550.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406077548
08/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $400.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406077546
08/25/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $225.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 406077544
06/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $6250.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405768022
06/24/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $7475.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766268
04/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $700.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766266
04/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $5625.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766264
04/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $5550.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766262
06/24/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766260
04/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766258
05/02/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4700.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766238
06/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $300.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405766236
01/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $4850.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405707008
01/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $5000.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704880
01/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704812
02/03/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3500.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704810
01/15/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3250.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704808
02/03/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3000.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704806
02/03/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1450.00 Details
Payment from Merck Sharp & Dohme Corporation
Payment Record ID 405704804
06/01/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1375.00 Details
Payment from Pfizer Inc.
Payment Record ID 405213948
02/03/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $1175.00 Details
Payment from Pfizer Inc.
Payment Record ID 405120648
04/07/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $3000.00 Details
Payment from Pfizer Inc.
Payment Record ID 404997952
05/02/2016 General (Non-Research) Cash or cash equivalent Consulting Fee $550.00 Details
Payment from Pfizer Inc.
Payment Record ID 403893504
04/15/2016 Research Cash or cash equivalent $41812.50 Details
Payment from Eli Lilly and Company
Paymment Research Study A 24-MONTH, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP, EFFICACY, SAFETY, TOLERABILITY, BIOMARKER, AND PHARMACOKINETIC STUDY OF AZD3293 IN EARLY ALZHEIMERS DISEASE -THE AMARANTH STUDY
Clinical Trials Gov ID NCT02245737
Payment Record ID 372520570
;